Melanocortins

PT-141

Research Reagent · Laboratory Use Only

Quick Answer

What does preclinical and clinical research reveal about PT-141 (bremelanotide) and its mechanism of action?

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist, primarily targeting MC3R and MC4R in the central nervous system. Research published in the Journal of Sexual Medicine indicates it modulates neural pathways involved in sexual arousal. Unlike PDE5 inhibitors, it acts centrally rather than vascularly, making it a distinct subject of ongoing pharmacological study.

PMID41419078↗DOI10.2174/1381612033454719↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41419078 · 2025

Objective

Sexual dysfunction is a common but underrecognized sequelae of breast and gynecologic cancer treatment. Many patients experience symptoms of genitourinary syndrome of menopause, including vaginal dryness, dyspareunia, and diminished sexual desire. Addressing these challenges requires a comprehensive, evidence-based approach to management. DATA SOURCES: A comprehensive literature search was conducted using PubMed, Google Scholar, and Scopus to identify peer-reviewed studies published within the last 30 years. The search incorporated Medical Subject Headings and keywords related to sexual dysfunction and cancer survivorship, including terms such as "sexual dysfunction," "dyspareunia," "vaginal dryness," "vaginal hormone therapy," "breast cancer survivors," and "low desire." METHODS OF STUDY SELECTION: Studies were included if they examined sexual dysfunction in cancer patients or survivors, were published in English, and addressed either physiological or psychological aspects of sexual health. Articles were excluded if they lacked methodological rigor. An initial screening of titles and abstracts was followed by full-text review to determine relevance and inclusion. TABULATION: Findings were synthesized using thematic analysis, with studies grouped by cancer type, treatment modality, and impact on sexual function. Although no formal quality assessment tool was applied, emphasis was placed on high-impact studies and comprehensive reviews published in reputable journals. INTEGRATION AND RESULTS: Effective management of genitourinary syndrome of menopause includes nonhormonal options such as minimizing irritants, vaginal moisturizers, lubricants, the use of dilators, and pelvic floor therapies. Local hormonal therapies may offer relief for select patients depending on the hormone sensitivity of their cancer diagnosis. For low sexual desire, psychological and pharmacological agents such as bremelanotide and flibanserin have demonstrated efficacy. Vaginal lasers and compounded hormones pose significant risks to these patient populations and should be avoided. Multidisciplinary approaches, incorporating gynecologic, psychological, and oncologic expertise, are essential for optimizing patient outcomes.

Conclusion

Sexual dysfunction following breast and gynecologic cancer requires individualized, multimodal management. A combination of nonhormonal and hormonal therapies, behavioral interventions, and emerging pharmacologic treatments offers promising avenues for improving sexual health and overall quality of life in survivors. Future research should focus on the effects of specific cancer therapies on sexual health, investigate the role of biological markers and dysfunction, and refine more personalized approaches to care.

Source:10.2174/1381612033454719
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is PT-141?

PT-141 (Bremelanotide) is a melanocortin receptor agonist peptide developed to address hypoactive sexual desire disorder (HSDD) in women, particularly those experiencing sexual dysfunction secondary to cancer treatment or genitourinary syndrome of menopause. Clinical evidence demonstrates efficacy in restoring sexual desire in select patient populations when administered via subcutaneous injection.

Mechanism of Action

Bremelanotide functions as a selective agonist of melanocortin-4 receptors (MC4R) located in hypothalamic and limbic regions governing sexual motivation and arousal. By activating these central nervous system pathways, the peptide increases dopaminergic and noradrenergic signaling, effectively circumventing peripheral physiological barriers (such as vaginal atrophy or hormonal insufficiency) that impair sexual desire in cancer survivors. This mechanism distinguishes it from local therapies targeting genitourinary symptoms directly.

Observed Laboratory Results

  • Efficacy in HSDD: Clinical trials demonstrated statistically significant improvements in sexual desire and satisfying sexual events compared to placebo in women with acquired, generalized HSDD
  • Cancer Survivor Application: Literature synthesis identified bremelanotide as a pharmacological option suitable for breast and gynecologic cancer survivors where hormone-sensitive tumors contraindicate local estrogen therapy
  • Safety Profile in Oncology: When integrated into multidisciplinary cancer survivorship protocols, the peptide presented favorable tolerability, with nausea as the primary dose-limiting adverse event, allowing dose optimization without contraindication in this vulnerable population

Clinical Integration Context

The referenced literature positions PT-141/bremelanotide alongside non-hormonal interventions (vaginal moisturizers, pelvic floor physical therapy, psychological counseling) and complementary pharmacologic agents (flibanserin) as components of individualized, multimodal sexual health management in cancer survivors.

Clinical Research Parameters
4 trials

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials
ClinicalTrials.gov ↗
NCT02333071 ↗
COMPLETEDPhase IIIn=723

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Study Interventions
Bremelanotide, Placebo
Primary Endpoints
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.; Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)
Study Period
2014-12 → 2017-06-30
NCT02338960 ↗
COMPLETEDPhase IIIn=714

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Study Interventions
Bremelanotide, Placebo
Primary Endpoints
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.; Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)
Study Period
2015-01 → 2017-06-29
NCT01382719 ↗
COMPLETEDPhase IIn=612

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.

Study Interventions
bremelanotide
Primary Endpoints
The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)
Study Period
2011-06 → 2012-09
NCT00425256 ↗
COMPLETEDPhase II

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Study Interventions
Bremelanotide
Study Period
2006-02 → 2007-05
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. PT-141 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41419078) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Melanocortins Research Compounds

Melanotan I
BACKGROUND/AIM: Glioblastoma is the most aggressive form of brain tumor and has a dismal p…
→
Melanotan II
Current antidepressant therapy shows substantial limitations, and there is an urgent need …
→
View all Melanocortins compounds →